NeuroBo Pharmaceuticals (NRBO) Stock Price, News & Analysis

Company Overview

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $2.35 to $2.45
• 50-Day Range: $2.22 to $3.44
• 52-Week Range: $2.08 to $6.75
• Volume: 26,224 shs
• Average Volume: 402,830 shs
• Market Capitalization: $20.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

NeuroBo Pharmaceuticals Stock Analysis - MarketRank™

NeuroBo Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 617th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

NeuroBo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

NeuroBo Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NeuroBo Pharmaceuticals are expected to grow in the coming year, from ($3.91) to ($1.33) per share.

Price to Book Value per Share Ratio

NeuroBo Pharmaceuticals has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.64% of the float of NeuroBo Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

NeuroBo Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroBo Pharmaceuticals has recently decreased by 20.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroBo Pharmaceuticals does not currently pay a dividend.

Dividend Growth

NeuroBo Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.64% of the float of NeuroBo Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

NeuroBo Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroBo Pharmaceuticals has recently decreased by 20.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.15

News Sentiment

NeuroBo Pharmaceuticals has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for NeuroBo Pharmaceuticals this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, NeuroBo Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,526.00 in company stock.

Percentage Held by Insiders

Only 1.05% of the stock of NeuroBo Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 1.37% of the stock of NeuroBo Pharmaceuticals is held by institutions.

NRBO Stock Analysis - Frequently Asked Questions

How have NRBO shares performed this year?

NeuroBo Pharmaceuticals' stock was trading at $3.70 at the beginning of the year. Since then, NRBO stock has decreased by 35.9% and is now trading at $2.37.
View the best growth stocks for 2024 here.

How were NeuroBo Pharmaceuticals' earnings last quarter?

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) announced its quarterly earnings results on Monday, November, 15th. The company reported ($38.40) EPS for the quarter, topping analysts' consensus estimates of ($43.20) by $4.80.

When did NeuroBo Pharmaceuticals' stock split?

NeuroBo Pharmaceuticals shares reverse split on the morning of Thursday, December 21st 2023. The 1-8 reverse split was announced on Thursday, December 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Who are NeuroBo Pharmaceuticals' major shareholders?

NeuroBo Pharmaceuticals' top institutional shareholders include Ferguson Wellman Capital Management Inc. (0.19%).
View institutional ownership trends.

How do I buy shares of NeuroBo Pharmaceuticals?

Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of NeuroBo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroBo Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD), General Electric (GE) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 11/22/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NRBO
• CUSIP: N/A
• CIK: 1638287
• Web: www.neurobopharma.com
• Phone: (857) 702-9600
• Fax: 734-293-0444
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +321.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-12,470,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -189.12%
• Return on Assets: -122.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.41
• Quick Ratio: 2.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.50 per share
• Price / Book: 1.58

Miscellaneous

• Outstanding Shares: 8,616,000
• Free Float: 8,526,000
• Market Cap: $20.42 million
• Optionable: Not Optionable
• Beta: -0.26